Fortrea Holdings FTRE 深 沪
等待开盘 10-16 09:30:00 美东时间
22.745
+1.405
+6.58%
华盛通- 最 高23.07
- 今 开21.93
- 成交量 290.97万股
- 最 低 21.63
- 昨 收 21.34
- 总市值 216.30万
- 52周最高 23.51
- 市盈率 静 --
- 换手率 3059.62%
- 52周最低 8.55
- 委 比 4.73%
- 总股本 9.51万
- 历史最高 41.02
- 量 比 1.86
- 振 幅 6.75%
- 历史最低 3.97
- 每 手 1
- 风险率 3.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Deutsche Bank Upgrades Fortrea Holdings to Buy, Raises Price Target to $25
Deutsche Bank analyst Justin Bowers upgrades Fortrea Holdings (NASDAQ:FTRE) from Hold to Buy and raises the price target from $20 to $25.
10-15 18:34
Court Dismisses Fortrea Holdings (FTRE) Securities Lawsuit Over Spin-Off Cost and Backlog Claims
A federal judge has dismissed a securities lawsuit against Fortrea Holdings Inc...
10-13 17:25
美股大行评级 | 花旗看高AMD至800美元！富国上调Meta目标价至1000美元
今日重点评级关注：Jones Trading：维持Opus Genetics"买入"评级，目标价从10美元升至17美元；Citizens：维持Rezolute"跑赢大市"评级，目标价从11美元升至15美元
10-07 17:30
美股大行评级 | 潜在涨幅600.93%！Ascendiant Capital上调Aytu BioPharma目标价至15美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14.5美元升至15美元；摩根大通：维持Annexon"超配"评级，目标价从14美元升至15美元
10-01 19:18
UBS Initiates Coverage On Fortrea Holdings with Neutral Rating, Announces Price Target of $22
UBS analyst Kevin Caliendo initiates coverage on Fortrea Holdings (NASDAQ:FTRE) with a Neutral rating and announces Price Target of $22.
09-30 20:16
Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion
Fortrea (NASDAQ:FTRE) signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million. The deal significantly enhances Fortrea’s position as a global clinical development partner by strengthening t...
09-03 01:31
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
Barclays Maintains Equal-Weight on Fortrea Holdings, Raises Price Target to $22
Barclays analyst Luke Sergott maintains Fortrea Holdings (NASDAQ:FTRE) with a Equal-Weight and raises the price target from $18 to $22.
07-30 18:46
Fortrea Holdings Q2 Adj. EPS $0.23 Beats $0.18 Estimate, Sales $678.200M Beat $647.465M Estimate
Fortrea Holdings (NASDAQ:FTRE) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.18 by 27.78 percent. This is a 21.05 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $678.200 millio...
07-29 18:31
